Inhibrx, Inc. Common Stock
INBX
INBX was delisted on the 29th of May, 2024.
61 hedge funds and large institutions have $538M invested in Inhibrx, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 8 reducing their positions, and 8 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 8
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
65% more capital invested
Capital invested by funds: $326M → $538M (+$212M)
11% more funds holding
Funds holding: 55 → 61 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$18.9M |
| 2 |
BlackRock
New York
|
+$18.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.61M |
| 4 |
Millennium Management
New York
|
+$4.88M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$3.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$3.3M |
| 2 |
Bank Julius Baer & Co
Zurich,
Switzerland
|
-$2.82M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.16M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$1.83M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$1.42M |
INBX Hedge Fund Activity: Q2 2021 in Review
61 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q2 2021, worth a combined $538M — up 65% from $326M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new INBX positions and 8 closed out — a net gain of 6 holders — while 28 added to existing stakes and 8 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $18.9M. The largest seller was Soleus Capital Management, cutting an estimated $3.3M.
- 61 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q2 2021, up from 55 in Q1 2021.
- Funds reported $538M of Inhibrx, Inc. Common Stock stock for Q2 2021, up 65% quarter-over-quarter.
- 14 funds opened new Inhibrx, Inc. Common Stock positions in Q2 2021 and 8 closed out, a net change of +6 holders.
- The largest Inhibrx, Inc. Common Stock buyer in Q2 2021 was Perceptive Advisors, an estimated $18.9M added.
- The largest Inhibrx, Inc. Common Stock seller in Q2 2021 was Soleus Capital Management, an estimated $3.3M sold.
Based on aggregated 13F filings for Q2 2021.